FDA approves gene therapy for genetic hearing loss amid systemic gaps in equitable healthcare access and indigenous genetic sovereignty debates
Original framing: “Regeneron wins FDA approval for first gene therapy for genetic hearing loss - Reuters” — Reuters (via Google News)
The original framing omits the historical exploitation of Indigenous and marginalised communities in genetic research, such as the Havasupai Tribe case where DNA samples were used without consent for unrelated studies. It also ignores the structural barriers in healthcare access that disproportionately affect low-income and rural populations, as well as the ethical debates surrounding genetic patenting and corporate control over biological data. Indigenous knowledge systems on hearing loss and traditional medicine are entirely absent, despite their potential contributions to holistic healthcare solutions.
Low structural omission detected in mainstream coverage.
The narrative is produced by Reuters, a Western-centric news outlet, and serves the interests of pharmaceutical corporations like Regeneron, investors, and regulatory bodies like the FDA. The framing obscures power structures by positioning gene therapy as a neutral technological advancement rather than a product of corporate-driven medical research with vested financial interests. It also marginalises public health advocates and Indigenous communities who critique the commodification of genetic material and the lack of inclusive clinical trial participation.
Scientifically, the FDA’s approval of Regeneron’s gene therapy for genetic hearing loss is based on clinical trial data demonstrating safety and efficacy in a subset of patients with a specific genetic mutation (OTOF). However, the trials may not fully represent diverse populations, as genetic variations across ethnic groups can affect treatment outcomes. Additionally, the long-term effects of gene therapy remain uncertain, and the high cost of such therapies raises questions about scalability and accessibility. The scientific narrative must also consider the ethical implications of germline editing, which could have unintended consequences for future generations.
The FDA’s approval of Regeneron’s gene therapy for genetic hearing loss exemplifies the tension between biomedical innovation and systemic inequities, echoing historical patterns of exploitation in genetic research.